Ridinilazole Versus Vancomycin for Initial C. Difficile Infection Ridinilazole Versus Vancomycin for Initial C. Difficile Infection

Ridinilazole, a novel, targeted-spectrum antimicrobial, was found to be non-inferior to vancomycin for treating initial Clostridium difficile infection (CDI), according to a study funded by the maker of ridinilazole (Summit Therapeutics, Abingdon, U.K.) and Wellcome Trust.Reuters Health Information
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Medscape Today News Source Type: news